Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
Open Access
- 18 September 2009
- journal article
- clinical trial
- Published by Springer Nature in BMC Cancer
- Vol. 9 (1), 333
- https://doi.org/10.1186/1471-2407-9-333
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialThe Lancet, 2008
- Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation TrialJournal of Clinical Oncology, 2007
- High predictive value of epidermal growth factor receptor phosphorylation but not of EGFRvIII mutation in resected stage I non-small cell lung cancer (NSCLC)Journal of Clinical Pathology, 2006
- Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosisLung Cancer, 2006
- Activated Epidermal Growth Factor Receptor–Stat-3 Signaling Promotes Tumor SurvivalIn vivoin Non–Small Cell Lung CancerClinical Cancer Research, 2005
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Phospho-Akt Overexpression in Non–Small Cell Lung Cancer Confers Significant Stage-Independent Survival DisadvantageClinical Cancer Research, 2004
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004
- Phosphorylation State-Specific AntibodiesThe American Journal of Pathology, 2003
- O-242 Gefitinib (‘Iressa’, ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer in IDEAL 1 and 2: tumor response is not clinically relevantly predictable from tumor EGFR membrane staining aloneLung Cancer, 2003